While the Medicare Board of Trustees reported that Part D drug spending in 2018 came in slightly higher than predicted, it lowered its projected growth rates for the next five years due to slower price growth and higher manufacturer rebates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,